croup
CROUP
Croup is a viral infection that causes erythema and edema of the tracheal walls and narrowing of the subglottic region. It is often characterized by an acute, rapidly progressing respiratory disease.
It is a medical emergency in children and requiring immediate treatment.
Most common causes are parainfluenza virus 1&2 and respiratory syncytial virus.
Occurrence of symptoms is usually at night and with abrupt onset and improve during daytime.

Croup References

  1. Cherry JD. Clinical Practice: Croup. N Engl J Med. 2008 Jan;358(4):384-391. http://www.nejm.org/doi/pdf/10.1056/NEJMcp072022. Accessed 19 Jul 2010. PMID: 18216359
  2. Fitzgerald DA, Kilham HA. Croup: assessment and evidence-based management. Med J Aust. 2003 Oct;179(7):372-377. https://www.mja.com.au/journal/2003/179/7/croup-assessment-and-evidence-based-management. Accessed 19 Jul 2010. PMID: 14503904
  3. Russell K, Wiebe N, Saenz A, et al. Glucocorticoids for croup. Cochrane Database Syst Rev. 2004;(1):CD001955. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001955.pub2/pdf. PMID: 14973975
  4. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  5. The Royal Children's Hospital Melbourne. Clinical Practice guidelines: croup (laryngotracheobronchitis). The Royal Children's Hospital Melbourne Web Site. http://www.rch.org.au/clinicalguide/guideline_index/Croup_Laryngotracheobronchitis/. Apr 2011. Accessed 29 Apr 2014.
  6. Muniz A. Croup: treatment & management. eMedicine Web Site. http://emedicine.medscape.com/article/962972-treatment. Jun 2015. Accessed 19 Jul 2010.
  7. Alberta Clinical Practice Guideline Working Group. Guideline for the diagnosis and management of croup. Alberta Medical Association Web Site. http://www.topalbertadoctors.org/download/252/croup_guideline.pdf. Jan 2008. Accessed 19 Jul 2010.
  8. Woods CR. Croup: pharmacologic and supportive interventions. UptoDate Web Site. http://www.uptodate.com/contents/croup-pharmacologic-and-supportive-interventions?source=search_result&search=croup&selectedTitle=3~55. Jan 2014. Accessed 29 Apr 2014.
  9. Mazza D, Wilkinson F, Turner T, Harris C; Health for Kids Guideline Development Group. Evidence based guideline for the management of croup. Aust Fam Physician. 2008 Jun;37(6 Spec No):14-20. http://www.racgp.org.au/afpbackissues/2008/200806/200806supplementcroup.pdf. PMID: 19142265
  10. Petrocheilou A, Tanou K, Kalampouka E, Malakasioti G, Giannios C, Kaditis AG. Viral croup: diagnosis and a treatment algorithm. Pediatr Pulmonol. 2014 May;49(5):421-429. http://onlinelibrary.wiley.com/doi/10.1002/ppul.22993/pdf. PMID: 24596395
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.